Compare Johnson & Johnson (JNJ) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Xpeng Inc - ADR — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while Xpeng Inc - ADR trades at $13.22 (market cap $12.96B). The key difference: Johnson & Johnson is far larger — about 46.2× Xpeng Inc - ADR's market cap, and Johnson & Johnson pays a 2.15% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| JNJ | XPEV | |
|---|---|---|
Market Cap | $598.96B | $12.96B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $28.07 |
52-Week Low | $164.36 | $12.09 |
Enterprise Value | $631.90B | $15.07B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
XPEV stock trades at $13.22, down 2.33% on the day, with a neutral technical outlook. The company reported revenue of $76.72 billion in 2025, but net losses persist, though the margin improved to -1.49%. Recent news highlights overseas expansion with the L03 SUV launch in Munich and progress in autonomous driving technology. Analyst consensus is bullish with a $17.00 price target, but cash flow volatility and competitive pressures remain concerns.
The outlook for XPEV hinges on execution of global expansion and new model launches to drive profitability. Investment opportunity lies in market share gains and technology leadership in EVs and AI, but risks include intense competition, reliance on Chinese market dynamics, and ongoing cash burn. The stock offers growth potential if the company can sustain revenue growth and narrow losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
